Logo

Autogenomics

Prescient Medicine, Erasmus MC Partner to Study Opioid Addiction Risk Test

Prescient offers a test that is designed to determine an individual's risk of opioid addiction by analyzing 16 genes in the brain's reward pathway.

Prescient Medicine Acquires AutoGenomics

Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.

FDA Grants Breakthrough Designation for AutoGenomics' Infiniti Neural Response Panel

The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.

Prescient Medicine Launches Addiction Risk Test Developed With AutoGenomics
Premium

The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications.

WuXi to Distribute AutoGenomics' MDx System in China

The companies will also collaborate on new diagnostic technologies and products that are specifically designed for Chinese patients.

Jul 24, 2015

AutoGenomics to Withdraw Planned IPO; Eyes Launch of New MDx Platform in Q1 2016
Premium

Feb 4, 2015

AutoGenomics Sets Price Range for Planned IPO, Anticipates up to $46.6M in Proceeds

Oct 8, 2014

AutoGenomics Seeks to Raise $60M in IPO

Jul 9, 2014

Genomas, Autogenomics Codeveloping Multiplex Genetic Test for Statin Efficacy and Adverse Events
Premium

Jul 7, 2014

Genomas, AutoGenomics Partner to Advance Dx to Personalize Statin Treatments

Apr 8, 2014

IP Watch: Epigenomics, Fluidigm, Sony, Life Tech, Others Win US Patents
Premium

Nov 4, 2013

MDx Firm AutoGenomics Withdraws IPO

Sep 4, 2013

Spartan to Continue Talks with FDA as it Aims for Point-of-Care Indication for CYP2C19 Test
Premium

Aug 29, 2013

FDA Clearance of Spartan Assay Inches CYP2C19 Genotyping Closer to Point of Care
Premium

Feb 25, 2013

Most Viewed Articles on GWDN Last Week: Feb 25, 2013

Feb 18, 2013

AutoGenomics Withdraws IPO for Second Time

Jan 23, 2013

AutoGenomics Lowers Proceeds Expected from IPO

Nov 2, 2012

AutoGenomics Reports Sharp Rise in Revenues for First Nine Months of 2012

Sep 27, 2012

AutoGenomics Targets $65M IPO

Jun 27, 2012

AutoGenomics Gets Health Canada OK for PGx System

Mar 28, 2012

FDA Disputes Claims that it Prematurely Updated Plavix Label with PGx Information
Premium

Mar 14, 2012

Does Lack of PGx Link in Recent Studies Foreshadow End of CYP2D6 Genotyping for Tamoxifen?
Premium

Feb 15, 2012

Dx Developers' Sales Pitch to Pharma Could be Key Factor in Marketing Some Tests
Premium

Jun 22, 2011

'Not Approvable' Letter Thwarts Nanosphere's Hopes to Launch FDA-Approved Plavix PGx Test
Premium

May 19, 2011

AutoGenomics Withdraws IPO

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.